Placental Transfer Efficiency of Neutralizing Antibodies on SARS-CoV-2 Vaccination before and after Pregnancy in Mexican Women.

Publication date: Jan 26, 2024

The protection of the neonate against pathogens depends largely on the antibodies transferred placentally from the mother; for this reason, maternal vaccination against emerging viruses, such as SARS-CoV-2, is of vital importance. Knowing some of the immunogenic factors that could alter the placental transfer of antibodies could aid in understanding the immune response and neonatal protection after maternal vaccination. In this study, we analyzed the efficiency of the placental transfer of binding and neutralizing antibodies, as well as some factors that could alter the passive immune response, such as the trimester of gestation at the time of immunization, the number of doses received by the mother and the type of vaccine. Binding IgG antibodies were detected by ELISA, and the detection of neutralizing antibodies was carried out using flow cytometry. Our results show efficient transfer rates (>1), which are higher when maternal vaccination occurs during the third trimester of gestation. Antibodies are detectable in mothers and their neonates after 12 months of maternal immunization, suggesting than the vaccination against COVID-19 before and during pregnancy in the Mexican population induces a lasting neutralizing response in mothers and their newborns.

Open Access PDF

Concepts Keywords
Antibodies COVID-19 vaccines
Covid IgG
Mexican immunity
Neonatal neutralizing antibodies
Women placental transfer


Type Source Name
disease VO efficiency
disease VO vaccination
disease VO Viruses
disease IDO immune response
disease VO time
disease VO immunization
disease VO vaccine
disease VO efficient
disease MESH COVID-19
disease VO population
drug DRUGBANK Coenzyme M
disease VO pregnant women
disease MESH maternal death
disease MESH complications
disease MESH preterm birth
disease MESH venous thromboembolism
disease MESH stillbirth
disease MESH live births
disease MESH death
disease VO Sputnik V
disease VO CoronaVac
disease VO effective
disease MESH infection
disease VO effectiveness
disease VO immunized
disease VO vaccinated
disease VO unvaccinated
disease VO dose
disease IDO history
disease IDO blood
drug DRUGBANK Aspartame
drug DRUGBANK Indoleacetic acid
disease VO antibody titer
disease VO inefficient
disease MESH rubella
disease MESH measles
pathway KEGG Measles
disease MESH whooping cough
disease MESH influenza
disease MESH hepatitis
disease VO primary vaccination
disease VO vaccination dose
disease VO Ad26.COV2.S
disease VO frequency
disease VO titer
disease VO vaccine efficacy
disease MESH twin pregnancies
disease MESH bleeding
disease VO vein
disease IDO assay
disease VO USA
drug DRUGBANK Rasagiline
drug DRUGBANK Immune Globulin Human
disease MESH Allergy

Original Article

(Visited 1 times, 1 visits today)